ARCA biopharma Announces Third Quarter 2022 Financial Results
WESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update.
Related news for (ABIO)
- arca biopharma announces completion of merger with oruka therapeutics and implementation of reverse stock split
- arca biopharma provides update regarding special dividend amount in connection with the proposed merger with oruka therapeutics
- arca biopharma announces 1-for-12 reverse stock split in connection with the proposed merger with oruka therapeutics
- arca biopharma declares special dividend in connection with the proposed merger with oruka therapeutics
- ARCA biopharma Announces 2023 Financial Results